Awarded contract

NHS National Generic Pharmaceuticals Wave 13

Details

Buyer
NHS England
Supplier(s)
131 suppliers
Value
GBP 192
Topic
Pharmaceutical products
Published
14 January 2022
Source
uk:find_a_tender

Tender description

Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Lot 1: Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus) Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 2: Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Lot 3: Lot 3 - CM/PHG/17/5532/02 Hospital Only Products Invitation to offer for NHS National Generic Pharmaceuticals Wave 13<br/>Offer reference number: CM/PHG/17/5532<br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority’s sole discretion) for a period or periods up to a total of 48 months.<br/><br/>Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Timeline

  1. Award date30 November 2021
  2. Award published14 January 2022
    Current notice

About the buyer

NHS England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.

Relevant CPV codes

  • 33600000 · Pharmaceutical products

AI insights

  • Is there a preferred supplier?
  • What are the buyers pain points?
  • What has the buyer previously procured?
  • What are the key requirements?
Sign-up to enrich

Decision makers

Connect with the people behind this procurement.

Contact nameJob titlePhone numberWork email
Head of Procurement+44 •••• ••••••
Commercial Director+44 •••• ••••••
Procurement Manager+44 •••• ••••••
Category Lead+44 •••• ••••••
Senior Buyer+44 •••• ••••••
Contracts Manager+44 •••• ••••••

6 similar open tenders

See more open tenders related to NHS National Generic Pharmaceuticals Wave 13.

Explore all open tenders

Related buyers

Buyers similar to NHS England.

View all buyers
BuyersCountValue
  1. NHS Property Services Ltd
    461
    £2.1bn
  2. UK Shared Business Services - UKSBS
    374
    £250.3m
  3. Sellafield Limited
    366
    £15.0bn
  4. Bank of England
    298
    £2.8bn
  5. Network Rail
    267
    £19.9bn
  6. Department of Health and Social Care
    266
    £903.0m
  7. Financial Conduct Authority
    255
    £517.2m
  8. Post Office Ltd
    203
    £1.0bn
  9. Nuclear Decommissioning Authority (NDA)
    143
    £900.1m
  10. Genomics England
    135
    £63.9m

Win more public sector contracts

Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.

Try for free